Otsuka has claimed FDA approval for its IgA nephropathy (IgAN) therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch. Anti-APRIL antibody Voyxact ...

Otsuka and Vera Therapeutics have both presented new data on drug candidates for IgA nephropathy (IgAN), striving to join a market which is becoming increasingly crowded. Vera Therapeutics reported ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Products Market Alerts MyCollection Price Database Become a Partner Gallery ...

Otsuka Holdings Co., Ltd. engages in the management of its group companies which are in the pharmaceuticals business. It operates through the following segments: Pharmaceuticals, Nutraceuticals, ...